NCT02176681 - A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Haemodialyzed, Type 2 Diabetes

Interventions

DRUG

Vildagliptin (Galvus)

Use Vildagliptin (50 mg/day) added to insulin during 3 months

DRUG

Insulin

Trial Locations (13)

CH de Dijon, Dijon

CH de Besançon, Besançon

CH de Nancy, Nancy

CH de Valenciennes, Valenciennes

AURAL Clinique Sainte Anne, Strasbourg

Clinique Sainte Anne, Strasbourg

Hôpitaux Universitaires de Strasbourg, Strasbourg

AURAL Strasbourg, Strasbourg

AURAL Colmar, Colmar

Hospices civils de Colmar, Colmar

AURAL Mulhouse, Mulhouse

CH de Mulhouse, Mulhouse

CH d'Amiens, Amiens